NSC243928 Treatment Induces Anti-Tumor Immune Response in Mouse Mammary Tumor Models
Cancers · 25.02.2023 · 15 (5) · 1468
DOI: 10.3390/cancers15051468 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 25.02.2023. Verfasst von Benson Chellakkan Selvanesan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, CSR NIH HHS, NIH, NCI.
Abstract (Originalsprache)
NSC243928 induces cell death in triple-negative breast cancer cells in a LY6K-dependent manner. NSC243928 has been reported as an anti-cancer agent in the NCI small molecule library. The molecular mechanism of NSC243928 as an anti-cancer agent in the treatment of tumor growth in the syngeneic mouse model has not been established. With the success of immunotherapies, novel anti-cancer drugs that may elicit an anti-tumor immune response are of high interest in the development of novel drugs to treat solid cancer. Thus, we focused on studying whether NSC243928 may elicit an anti-tumor immune response in the in vivo mammary tumor models of 4T1 and E0771. We observed that NSC243928 induced immunogenic cell death in 4T1 and E0771 cells. Furthermore, NSC243928 mounted an anti-tumor immune response by increasing immune cells such as patrolling monocytes, NKT cells, B1 cells, and decreasing PMN MDSCs in vivo. Further studies are required to understand the exact mechanism of NSC243928 action in inducing an anti-tumor immune response in vivo, which can be used to determine a molecular signature associated with NSC243928 efficacy. NSC243928 may be a good target for future immuno-oncology drug development for breast cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
- Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA.
- Department of Anatomy, Physiology, and Genetics, Center for Military Precision Health, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
- Innovation Center for Biomedical Informatics, Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA.
- John P. Murtha Cancer Center, Bethesda, MD 20814, USA.
ORCID-Profile: Deepak Rohila, Yuriy Gusev, Sara Contente, Geeta Upadhyay
Förderung
- NCI NIH HHS
- CSR NIH HHS
- NIH, NCI
- DOD, USUHS
- Biomedical Instrumentation Center, USUHS
- The American Genome Center, USUHS
Zitieren
APA
Selvanesan, B. C., de Mingo Pulido, A., Varghese, S., Rohila, D., Hupalo, D., Gusev, Y., Contente, S., Wilkerson, M. D., Dalgard, C. L., & Upadhyay, G. (2023). NSC243928 Treatment Induces Anti-Tumor Immune Response in Mouse Mammary Tumor Models. Cancers, 15(5), 1468. https://doi.org/10.3390/cancers15051468
Vancouver
Selvanesan BC, de Mingo Pulido A, Varghese S, Rohila D, Hupalo D, Gusev Y, et al. NSC243928 Treatment Induces Anti-Tumor Immune Response in Mouse Mammary Tumor Models. Cancers. 2023;15(5):1468. doi:10.3390/cancers15051468
BibTeX
@article{Selvanesan2023,
author = {Selvanesan, Benson Chellakkan and de Mingo Pulido, Alvaro and Varghese, Sheelu and Rohila, Deepak and Hupalo, Daniel and Gusev, Yuriy and Contente, Sara and Wilkerson, Matthew D and Dalgard, Clifton L and Upadhyay, Geeta},
title = {NSC243928 Treatment Induces Anti-Tumor Immune Response in Mouse Mammary Tumor Models},
journal = {Cancers},
year = {2023},
volume = {15},
number = {5},
pages = {1468},
doi = {10.3390/cancers15051468}
}
EUVIMED